HyperlipidemiasHyperlipidemia, Familial CombinedHypolipidemic AgentsTriglyceridesXanthomatosisPeriarthritisCholesterolLipidsCholesterol, LDLAnticholesteremic AgentsHypercholesterolemiaLipoproteinsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, HDLFenofibrateHyperlipoproteinemia Type IIAzetidinesRisk FactorsDiabetes MellitusSimvastatinApolipoproteins BHypertensionLipoproteins, VLDLLipoproteins, LDLCardiovascular DiseasesObesityMalaysiaDiabetes Mellitus, Type 2Coronary DiseaseDiabetes ComplicationsTendinopathyBlood GlucoseArthritisHypertriglyceridemiaPrevalenceInsulinRegression AnalysisHyperlipoproteinemia Type IVKidney TransplantationMyocardial InfarctionCase-Control StudiesProspective StudiesApolipoproteins ETreatment OutcomeLipid MetabolismBody Mass IndexApolipoproteins CAge FactorsApolipoprotein E2Drug Therapy, CombinationDouble-Blind MethodPractice Guidelines as TopicApolipoprotein C-IIILipoprotein LipaseBiological MarkersArteriosclerosisFollow-Up StudiesSmokingApolipoproteinsCholesterol, VLDLLiverCross-Sectional StudiesGynostemmaReceptors, LDLDietary FatsHyperlipoproteinemia Type IIIAtherosclerosisPoloxamerHeptanoic AcidsDiet, AtherogenicApolipoprotein A-ICholesterol, DietaryMice, Inbred C57BLPostprandial PeriodBezafibrateEpichlorohydrinFatty LiverInsulin ResistanceDyslipidemiasApolipoproteins AHyperlipoproteinemiasBody WeightPyrrolesNephrotic SyndromeHyperlipoproteinemia Type VDisease Models, AnimalApolipoprotein E3Fatty Acids, NonesterifiedGemfibrozilMice, KnockoutGadiformesApolipoprotein B-48Lipoproteins, IDLHyperglycemiaPravastatinChylomicronsPhytotherapyDiet, High-FatApolipoprotein A-IILipase